Skip to main content

Advertisement

Table 2 Summary of efficacy endpoints

From: Evaluation of etoricoxib in patients undergoing total knee replacement surgery in a double-blind, randomized controlled trial

Endpoints Placebo Etoricoxib 90 mg p-Value vs. placebo Etoricoxib 120 mg p-Value vs. placebo Ibuprofen 1800 mg*
Primary endpoints Value (95% CI)      
LS Mean Change from Baseline Average Pain Intensity at Rest over Days 1–3 (0–10 point NRS) -3.39 (-3.74, -3.04) -3.93 (-4.17, -3.69) p = 0.018 -3.87 (-4.11, -3.64) p = 0.009 -3.83 (-4.07, -3.59)
LS Geometric Mean Total Daily Dose of Morphine Over Days 1 to 3 mg 13.4 (11.2, 16.0) 8.87 (7.88, 9.97) p < 0.001 9.25 (8.26, 10.4) p < 0.001 8.82 (7.85, 9.91)
Raw Geometric Mean Total Daily Dose Over Days 1 to 3 13.5 8.84 N/A 9.26 N/A 8.83
Other endpoints       
LS Mean Change from Baseline Average Pain Intensity at Rest over Days 4–7 (0–10 point NRS) -4.03 (-4.39, -3.67) -4.74 (-5.00, -4.49) p < 0.001 -4.92 (-5.16, -4.67) p < 0.001 -4.70 (-4.95, -4.45)
Postoperative Morphine Consumption (mg) 3.43 (2.69, 4.36) 1.72 (1.46, 2.02) N/A 1.70 (1.46, 1.99) N/A 2.06 (1.76, 2.41)
LS Geometric Mean Total Daily Dose Over Days 4 to 7
Raw Geometric Mean Total Daily Dose Over Days 4 to 7 3.49 1.71 N/A 1.70 N/A 2.06
LS Mean Change from Baseline in Pain Intensity at Knee Flexion over Days 1 to 3 (0- to 10-point NRS) -1.59 (-2.00, -1.17) -1.96 (-2.24, -1.68) p = 0.057 -2.05 (-2.32, -1.78) p = 0.129 -2.00 (-2.28, -1.72)
LS Mean Change from Baseline in Pain Intensity at Knee Flexion over Days 4 to 7 (0- to 10-point NRS) -3.61 (-4.05, -3.18) -4.78 (-5.08, -4.48) p < 0.001 -5.16 (-5.45, -4.87) p < 0.001 -4.56 (-4.85, -4.26)
  1. *p-values were not calculated for the comparison of ibuprofen vs. placebo.